NOVO NORDISK – Rybelsus (Semaglutide) – 7 mg Tablets
Supplied in a box containing 10 x 7 mg oral tablets.
Active Ingredient: Semaglutide.
Indications:
Rybelsus is indicated for adults with type 2 diabetes to improve blood sugar control when diet and exercise alone are insufficient. It may also support weight management as part of a diabetes treatment plan.
Administration:
Taken orally once daily on an empty stomach, at least 30 minutes before any food, drink, or other medication, with no more than 4 ounces of water. The 7 mg dose is often prescribed following an initial 3 mg starting dose, as guided by a healthcare provider.
Effects:
Rybelsus works as a GLP-1 receptor agonist, promoting insulin secretion, reducing glucagon release, and slowing gastric emptying. This action helps regulate blood sugar and can aid in reducing appetite, which may contribute to weight management.
Side Effects:
Common side effects include nausea, upset stomach, and decreased appetite. Less common but serious effects may include pancreatitis, kidney issues, and severe gastrointestinal symptoms.
Contraindications:
Not recommended for individuals with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disorders. Regular monitoring of blood glucose levels and overall health markers is advised for safe and effective treatment.